Glaukos Corporation $GKOS Stock Holdings Lessened by Allianz Asset Management GmbH

Allianz Asset Management GmbH cut its stake in shares of Glaukos Corporation (NYSE:GKOS) by 8.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 58,654 shares of the medical instruments supplier’s stock after selling 5,374 shares during the period. Allianz Asset Management GmbH owned approximately 0.10% of Glaukos worth $4,783,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of GKOS. Norges Bank acquired a new position in shares of Glaukos during the 2nd quarter worth $76,314,000. Primecap Management Co. CA increased its position in Glaukos by 50.0% during the second quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock worth $188,814,000 after buying an additional 609,523 shares during the last quarter. AustralianSuper Pty Ltd bought a new position in Glaukos during the second quarter valued at about $41,946,000. William Blair Investment Management LLC lifted its position in shares of Glaukos by 52.4% in the second quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock worth $117,347,000 after buying an additional 390,805 shares during the last quarter. Finally, Champlain Investment Partners LLC bought a new stake in shares of Glaukos during the 2nd quarter worth about $37,497,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Down 0.4%

GKOS opened at $112.80 on Wednesday. The firm has a market cap of $6.48 billion, a price-to-earnings ratio of -73.25 and a beta of 0.70. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. The firm’s 50-day simple moving average is $114.63 and its 200-day simple moving average is $97.73. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $161.78.

Analysts Set New Price Targets

Several brokerages recently issued reports on GKOS. Wells Fargo & Company boosted their price target on Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Thursday, January 22nd. Stephens upped their target price on Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 2nd. Stifel Nicolaus raised their target price on Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, William Blair raised shares of Glaukos to a “strong-buy” rating in a report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $132.54.

Insider Activity

In other Glaukos news, Director Marc Stapley sold 15,000 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total transaction of $1,915,650.00. Following the completion of the sale, the director directly owned 37,449 shares of the company’s stock, valued at approximately $4,782,611.79. The trade was a 28.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total transaction of $536,350.00. Following the transaction, the director owned 34,905 shares in the company, valued at approximately $3,744,259.35. The trade was a 12.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 329,655 shares of company stock worth $37,752,234. 6.40% of the stock is owned by company insiders.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.